The increasing prevalence and severity of Gram-negative infections (GNIs) caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens have emerged as a global public health concern. Recent surveillance studies find that an increasing proportion of ESBL-producing pathogens are also associated with resistance to other classes of antibiotics, further limiting therapeutic options. As such, new antibiotics with activity against ESBL-producing Gram-negative pathogens represent a key unmet need in the GNI therapy market.

Table of contents

  • Hospital-Treated Gram-Negative Infections - Unmet Need - Detailed, Expanded Analysis: Gram-Negative Infections Due To Extended-Spectrum Beta-Lactamase-Producing Pathogens
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in GNIs due to ESBL-Producing Pathogens
        • Importance of Efficacy Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in GNIs due to ESBL-Producing Pathogens — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Therapies for Gram-Negative Infections due to ESBL-Producing Pathogens
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens — United States
        • Overall Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens — Europe
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Convenience of Administration Attributes — Europe
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Non-Clinical Attributes — United States
        • Relative Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens Across Select Non-Clinical Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed ID Specialists' Satisfaction with the Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed ID Specialists' Satisfaction with the Performance of Key Therapies for GNIs due to ESBL-Producing Pathogens on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in GNIs due to ESBL-Producing Pathogens
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in GNIs due to ESBL-Producing Pathogens — United States
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in GNIs due to ESBL-Producing Pathogens — Europe
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in GNIs due to ESBL-Producing Pathogens — United States
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in GNIs due to ESBL-Producing Pathogens — Europe
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in GNIs due to ESBL-Producing Pathogens — United States
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in GNIs due to ESBL-Producing Pathogens — Europe
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in GNIs due to ESBL-Producing Pathogens — United States
        • Surveyed ID Specialists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in GNIs due to ESBL-Producing Pathogens — Europe
      • Unmet Need in GNIs due to ESBL-Producing Pathogens and Related Indications
        • Surveyed ID Specialists' Ascribed Level of Unmet Need in GNIs due to ESBL-Producing Pathogens and Related Indications — United States
        • Surveyed ID Specialists' Ascribed Level of Unmet Need in GNIs due to ESBL-Producing Pathogens and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the GNIs due to ESBL-Producing Pathogen Market and Emerging Therapy Insights
        • Opportunity: A Novel Carbapenem-Sparing Therapy with Comparable Efficacy and Safety Profile
        • Opportunity: An Effective Novel Therapy in an Interchangeable IV/Oral Formulation and/or with Less-Frequent Dosing
        • Opportunity: Physician Familiarity
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • GNIs due to ESBL-Producing Pathogens Target Product Profile: Attribute Importance
        • GNIs due to ESBL-Producing Pathogens Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • GNIs due to ESBL-Producing Pathogens Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • GNIs due to ESBL-Producing Pathogens Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Gram-Negative Infections due to ESBL-Producing Pathogens Market Simulations: Target Product Profiles Included in Scenario 1
        • GNIs due to ESBL-Producing Pathogens Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • GNIs due to ESBL-Producing Pathogens Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Gram-Negative Infections due to ESBL-Producing Pathogens Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Jiamin Zhuo, Ph.D.

Jiamin Zhuo, Ph.D., is a business insights analyst on the Infectious, Niche, and Rare Diseases team at DRG, part of Clarivate. He provides expert insight into the commercial aspects of drug development and market dynamics in bacterial infections, including gram-negative infections and Methicillin-resistant Staphylococcus aureus. He earned his Ph.D. at the Mayo Graduate School of the Mayo Clinic in Minnesota and his B.Sc. in physiology from Peking University in China. Prior to joining DRG, Dr. Zhuo was a postdoctoral fellow at Boston University and MIT, where he gained extensive experience in quantitative research methods.